Advertisement
U.S. markets open in 4 hours 37 minutes
  • S&P Futures

    5,306.50
    -1.75 (-0.03%)
     
  • Dow Futures

    40,145.00
    +1.00 (+0.00%)
     
  • Nasdaq Futures

    18,497.50
    -6.25 (-0.03%)
     
  • Russell 2000 Futures

    2,133.70
    -4.70 (-0.22%)
     
  • Crude Oil

    81.83
    +0.48 (+0.59%)
     
  • Gold

    2,217.60
    +4.90 (+0.22%)
     
  • Silver

    24.58
    -0.18 (-0.72%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2608
    -0.0030 (-0.24%)
     
  • USD/JPY

    151.3960
    +0.1500 (+0.10%)
     
  • Bitcoin USD

    70,796.34
    +1,003.71 (+1.44%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.47
    +28.49 (+0.36%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients

  • Inventiva (NASDAQ: IVA) has signed a €50 million bullet credit facility agreement with the European Investment Bank.

  • The company plans to use the facility for its preclinical and clinical pipeline, including to help fund a portion of its Phase 3 clinical trial of lanifibranor in patients with non-alcoholic steatohepatitis (NASH).

  • Related: Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor.

  • The facility is divided into two tranches of €25 million each. The disbursement of Tranche A is subject to the completion of certain conditions precedent specified in the credit facility agreement.

  • Tranche B is subject to the full drawdown of Tranche A and the achievement of certain conditions precedents.

  • It is expected that the reimbursement of the interests and capital of this credit facility will happen after the publication of the headline results of part 1 of the Phase 3 trial of lanifibranor in patients with NASH, expected in 2H 2024.

  • Price Action: IVA shares are up 3.40% at $9.10 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement